Profit Or Loss [Abstract]

OSE Immunotherapeutics - Filing #856037

Concept 2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
Profit or loss [abstract]
Profit (loss) [abstract]
Revenue
18 302 EUR
26 306 EUR
Profit (loss) from operating activities
18 476 EUR
16 625 EUR
Finance income
2 079 EUR
267,000 EUR
Finance costs
1 624 EUR
856,000 EUR
Profit (loss) before tax
18 022 EUR
17 213 EUR
Tax expense (income)
263,000 EUR
364,000 EUR
Profit (loss)
17 760 EUR
17 760 EUR
16 850 EUR
16 850 EUR
Profit (loss), attributable to [abstract]
Profit (loss), attributable to owners of parent
17 760 EUR
16 850 EUR
Earnings per share [text block]
Earnings per share [abstract]
Earnings per share [line items]
Basic earnings per share [abstract]
Basic earnings (loss) per share
96.00
93.00
Diluted earnings per share [abstract]
Diluted earnings (loss) per share
96.00
93.00

Talk to a Data Expert

Have a question? We'll get back to you promptly.